Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.
GW Pharmaceuticals (GWPH) - Get Report : In an exclusive "Executive Decision" segment, Cramer spoke with Justin Gover, CEO of GW Pharmaceuticals, a stock that surged 17% today on news of positive clinical trial data for a drug to treat pediatric epilepsy. Shares of GW Pharma are up 81.5% so far in 2016.
Gover said epilepsy is a complex disease to treat and patients in this study had tried on average 10 different drugs but were still having three seizures a day. Using GW's treatment, the frequency of those seizures dropped by 42%.
Gover explained cannabis, the focus of GW's research, contains a large number of different molecules that have the potential to be of medicinal value. GW has been researching the plant for 18 years and developing applications for pain, cancer, inflammatory diseases and most recently for diseases that affect the central nervous system.
Gover also added that unlike smoking cannabis, using the plant as a medicinal ingredient insures safety and control in manufacturing to verify dosages, all of which are principles of modern medicine.
Cramer called today's announcement an important breakthrough for patients in need.
Apple (AAPL) - Get Report : Shares of Apple are up 26% from their May lows and Cramer said this core position Action Alerts PLUS has a lot more room to run thanks to the high-profile recall of Samsung's (SSNLF) flagship Galaxy Note 7.
After two quarters of declining iPhone sales earlier this year, many analysts felt that Apple's best days were behind it. But that all changed when Samsung, sensing an opportunity, tried to leapfrog Apple but moving up the launch of it's Note 7 and adding tons of new features.
That strategy proved to be flawed, however, as battery malfunctions led to several phones exploding or catching on fire. The subsequent recall has been disastrous for Samsung, Cramer noted, and has given users around the globe a real reason to switch to iPhone.
Making matters worse, many Samsung users are reporting that their replacement phones do not have the battery life of their original.
Cramer said Samsung was simply too ambitious with its new phone and now is paying a hefty price as its brand is suffering immensely. Meanwhile, Apple is seeing strong demand for its iPhone, which should continue into the holiday season.
Align Technology (ALGN) - Get Report : In his second "Executive Decision" segment, Cramer spoke with with Joe Hogan, president and CEO of Align Technology, makers of InvisAlign orthodontic products. Shares of Align are up 41% in 2016.
Hogan said Align's growth stems from both expanding their footprint overseas and having deeper penetration of products here at home. He said 75% of orthodontic cases in the U.S. are for teens, while Align has traditionally focused its products on adults.
Compared to traditional braces, which glue metal directly to your teeth, Align's removable plastic inserts offer many advantages, Hogan said, and 50% to 60% of all orthodontic cases can use Align's products.
When asked why penetration is not higher, Hogan explained Align is essentially the digitization of an analog process and more education is needed to make dentists more comfortable with the technology.
Cramer said Align is yet another example of a non-economically sensitive stock that can be bought on fears of the election or of rising interest rates.
To read a full recap of "Mad Money" on CNBC, click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
At the time of publication, Cramer's Action Alerts PLUS had a position in AAPL.